Dynamic Technology Lab Private Ltd cut its holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 24.3% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 15,521 shares of the biopharmaceutical company’s stock after selling 4,989 shares during the quarter. Dynamic Technology Lab Private Ltd’s holdings in Vanda Pharmaceuticals were worth $278,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of VNDA. Birchview Capital LP boosted its position in Vanda Pharmaceuticals by 25.9% during the 2nd quarter. Birchview Capital LP now owns 68,000 shares of the biopharmaceutical company’s stock worth $1,108,000 after acquiring an additional 14,000 shares during the last quarter. State of Wisconsin Investment Board acquired a new position in Vanda Pharmaceuticals during the 2nd quarter worth approximately $538,000. Vanguard Group Inc. boosted its position in Vanda Pharmaceuticals by 7.5% during the 2nd quarter. Vanguard Group Inc. now owns 2,680,895 shares of the biopharmaceutical company’s stock worth $43,698,000 after acquiring an additional 186,548 shares during the last quarter. AJO LP boosted its position in Vanda Pharmaceuticals by 94.2% during the 2nd quarter. AJO LP now owns 541,927 shares of the biopharmaceutical company’s stock worth $8,833,000 after acquiring an additional 262,833 shares during the last quarter. Finally, Northern Trust Corp boosted its position in Vanda Pharmaceuticals by 16.5% during the 2nd quarter. Northern Trust Corp now owns 597,928 shares of the biopharmaceutical company’s stock worth $9,747,000 after acquiring an additional 84,834 shares during the last quarter. Institutional investors and hedge funds own 88.45% of the company’s stock.

VNDA has been the subject of a number of recent research reports. Zacks Investment Research downgraded Vanda Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, October 26th. ValuEngine downgraded Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, October 26th. Jefferies Group reaffirmed a “buy” rating and set a $21.00 price target on shares of Vanda Pharmaceuticals in a research report on Tuesday, August 29th. Finally, Oppenheimer reaffirmed a “buy” rating and set a $21.00 price target on shares of Vanda Pharmaceuticals in a research report on Thursday, September 14th. One analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the company. The company has an average rating of “Buy” and an average price target of $21.50.

Shares of Vanda Pharmaceuticals Inc. (VNDA) opened at $13.70 on Tuesday. Vanda Pharmaceuticals Inc. has a 12 month low of $11.90 and a 12 month high of $18.99.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.10). Vanda Pharmaceuticals had a negative return on equity of 10.99% and a negative net margin of 9.01%. The company had revenue of $41.30 million for the quarter, compared to analysts’ expectations of $43.90 million. During the same quarter in the prior year, the business posted ($0.01) EPS. The business’s revenue was up 7.3% compared to the same quarter last year. sell-side analysts anticipate that Vanda Pharmaceuticals Inc. will post -0.42 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This piece of content was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another website, it was stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/12/05/vanda-pharmaceuticals-inc-vnda-shares-sold-by-dynamic-technology-lab-private-ltd.html.

Vanda Pharmaceuticals Profile

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Institutional Ownership by Quarter for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Stock Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.